TEVA — Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $4 billion, down 1% year-over-year (up 7% excluding Japan divestment and generic REVLIMID).
• Adjusted EBITDA: $1.1 billion, up 2%.
• Non-GAAP EPS: $0.53, a 2% increase from Q1 2025.
• Free Cash Flow: $200 million, a significant increase of 76%.
• Net Debt to EBITDA: 2.42x.
• Gross Margin: 52.9%, better than expectations, driven by innovative product growth.

2. Strategic Updates and Business Highlights

• Pivot to Growth Strategy: Focused on four pillars: growth engines, innovation, sustaining generics, and business focus. Progress noted in innovative products (AUSTEDO, UZEDY, AJOVY) driving growth.
• Acquisition of Emalex Bioscience: First acquisition under the Pivot to Growth strategy, acquiring ecopipam for Tourette syndrome, expected to enhance CNS portfolio and align with strategic goals.
• Innovative Portfolio Growth: Innovative products grew 41%, with AUSTEDO reaching $559 million (up 41%), UZEDY at $63 million (up 62%), and AJOVY at $196 million (up 35%).
• Biosimilars Expansion: 11 biosimilars on the market, with plans for more, contributing to generics revenue.

3. Forward Guidance and Outlook

• 2026 Guidance: Reaffirmed with expectations for revenue growth in mid-single digits, non-GAAP operating income of 30%, and net debt to EBITDA below 2x by 2027.
• Emalex Acquisition Impact: Expected to be accretive to non-GAAP EPS starting in 2028, with a gross margin profile of approximately 80%.
• Innovative Product Pipeline: Anticipated milestones including data readouts for several products, with potential peak sales exceeding $10 billion.

4. Bad News, Challenges, or Points of Concern

• Generics Revenue Decline: Generics revenue down 13%, primarily due to the loss of revenue from generic REVLIMID, with expectations for continued pressure in the generics segment.
• Market Dynamics: Concerns about the impact of the IRA on AUSTEDO revenue in Q4 2026 and potential destocking issues affecting future quarters.
• Geopolitical Risks: Monitoring the situation in the Middle East, with nominal increases in transportation costs noted but no material impact on 2026 guidance.

5. Notable Q&A Insights

• Emalex Acquisition Synergies: Management highlighted synergies in patient services and sales force capabilities, particularly in pediatric markets.
• Peak Sales Potential: While peak sales guidance for ecopipam was not provided, management emphasized the significant unmet medical need in pediatric Tourette syndrome.
• AUSTEDO Growth Concerns: Analysts questioned the company's conservative growth guidance for 2027, given the strong performance in Q1 and upcoming product launches.
• Regulatory Confidence: Management expressed confidence in the regulatory pathway for ecopipam, citing robust data from previous studies and minimal safety concerns.
• Capital Allocation Strategy: Plans for share buybacks and potential future acquisitions were discussed, emphasizing a disciplined approach to capital allocation.

This summary encapsulates the key points from Teva's Q1 2026 earnings call, highlighting financial performance, strategic initiatives, outlook, and notable discussions from the Q&A session.